Comparisons of therapies in different scenarios help complete the puzzle

Abstract

Get full access to this article

View all access options for this article.

References

Lorscheider

Benkert

Lienert

et al . Comparative analysis of natalizumab versus fingolimod as second line treatment in relapsing-remitting multiple sclerosis. Mult Scler 2018; 24: 777–785.

Barbin

Rousseau

Jousset

et al . Comparative efficacy of fingolimod vs natalizumab: A French multicenter observational study. Neurology 2016; 86: 771–778.

Baroncini

Ghezzi

Annovazzi

et al . Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies. Mult Scler 2016; 22: 1315–1326.

Prosperini

Saccà

Cordioli

et al . Real-world effectiveness of natalizumab and fingolimod compared with self-injectable drugs in non-responders and in treatment-naïve patients with multiple sclerosis. J Neurol 2017; 264: 284–294.

Kalincik

Horakova

Spelman

et al . Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis. Ann Neurol 2015; 77: 425–435.

Koch-Henriksen

Magyari

Sellebjerg

et al . A comparison of multiple sclerosis clinical disease activity between patients treated with natalizumab and fingolimod. Mult Scler 2017; 23: 234–241.